CBD for Seizures: How Cannabis Helps Epilepsy Patients

In 2018, the FDA approved Epidiolex — a pharmaceutical-grade CBD extract — for treatment-resistant epilepsy, marking the first time a cannabis-derived medication received federal approval. This wasn't a marginal decision: the approval was based on rigorous Phase III clinical trials showing that CBD reduced seizure frequency by 40–50% in patients whose seizures hadn't responded to conventional anticonvulsant medications. For the estimated 1 million Americans with drug-resistant epilepsy, this was a breakthrough. But FDA-approved Epidiolex is just one form of CBD — many Florida patients achieve similar or better results with whole-plant medical cannabis products available at licensed dispensaries. This guide covers the science, the evidence, and the practical considerations for epilepsy patients considering medical marijuana.

How CBD Stops Seizures: The Mechanisms

Seizures occur when neurons in the brain fire excessively and synchronously, creating an electrical storm that disrupts normal function. CBD reduces seizure activity through multiple mechanisms that are distinct from conventional anticonvulsants. CBD modulates GPR55 receptors — a type of receptor that, when activated, increases neuronal excitability. By blocking GPR55, CBD reduces the likelihood of the excessive neural firing that triggers seizures (Kaplan et al., Journal of Physiology, 2017). CBD enhances the activity of TRPV1 channels, which when desensitized by sustained CBD activation, reduce neuronal excitability. CBD increases the concentration of anandamide — the body's natural cannabinoid — by inhibiting the FAAH enzyme that breaks it down. Higher anandamide levels have anticonvulsant effects through CB1 receptor activation. CBD also modulates intracellular calcium signaling, reducing the calcium influx that drives sustained neuronal firing. These mechanisms are complementary to conventional anticonvulsants (which typically work through sodium channel blockade or GABA enhancement), meaning CBD can be effective even when standard medications aren't — and can be safely added to existing anticonvulsant regimens.

The Landmark Clinical Trials

The evidence for CBD in epilepsy is among the strongest in all of cannabis medicine. The pivotal Devinsky et al. trial (New England Journal of Medicine, 2017) was a randomized, double-blind, placebo-controlled study of 120 patients with Dravet syndrome — a severe pediatric epilepsy. CBD reduced median monthly convulsive seizure frequency from 12.4 to 5.9 (a 39% reduction) compared to a 13% reduction with placebo. A companion trial by Devinsky et al. (NEJM, 2018) studied 225 patients with Lennox-Gastaut syndrome and found CBD reduced monthly drop seizures by 41.9% versus 17.2% with placebo. A Cochrane systematic review by Stockings et al. (2018) analyzed all available RCTs and concluded that CBD as an adjunctive treatment achieved a 50% or greater seizure reduction in significantly more patients than placebo. Long-term follow-up studies (Szaflarski et al., Epilepsia, 2021) showed sustained seizure reduction over 3+ years with no tolerance development, confirming that CBD's anticonvulsant effects are durable.

Epidiolex vs. Whole-Plant Cannabis for Epilepsy

Epidiolex is a 99%+ pure CBD extract — pharmaceutical grade, FDA-approved, and available by prescription. It costs approximately $32,500/year without insurance (though most insurers cover it for approved indications). Whole-plant cannabis products from Florida dispensaries contain CBD along with other cannabinoids (trace THC, CBG, CBN) and terpenes that may enhance anticonvulsant effects through the entourage effect. Several observational studies suggest whole-plant cannabis products may be more effective than purified CBD alone. A retrospective study by Pamplona et al. (Frontiers in Neurology, 2018) compared CBD-rich extracts to purified CBD in epilepsy patients and found that CBD-rich extracts achieved a lower effective dose (6.1 mg/kg/day vs. 25.3 mg/kg/day for purified CBD) and a higher responder rate (71% vs. 46% achieved >50% seizure reduction). The trace THC in whole-plant products may contribute to this enhanced effect — THC itself has anticonvulsant properties at low doses. For Florida patients, whole-plant CBD products from dispensaries offer a more affordable alternative to Epidiolex, typically costing $100–300/month depending on the dose required.

Dosing CBD for Seizures

CBD dosing for epilepsy is higher than for most other conditions. The FDA-approved Epidiolex dose starts at 2.5 mg/kg twice daily and increases to a maintenance dose of 5 mg/kg twice daily (with a maximum of 10 mg/kg twice daily for refractory cases). For a 150-pound (68 kg) adult, this translates to a starting dose of 170mg twice daily and a maintenance dose of 340mg twice daily — significantly higher than the 25–50mg doses used for anxiety or pain. With whole-plant cannabis products, effective doses may be lower due to the entourage effect, but patients should still expect to use substantially more CBD than for other conditions. Start with 2.5 mg/kg/day divided into two doses and increase by 2.5 mg/kg/day weekly until seizure frequency decreases or side effects limit further increases. Common side effects at higher doses include drowsiness, decreased appetite, and diarrhea — these are usually manageable and often diminish after the first few weeks. Important: CBD inhibits certain liver enzymes (CYP3A4, CYP2C19) and can increase blood levels of some anticonvulsants, particularly clobazam and valproate. Your neurologist should monitor anticonvulsant levels after starting CBD.

THC and Seizures: A Complex Relationship

While CBD gets the headlines, THC's role in epilepsy is more nuanced than many realize. At low doses, THC has anticonvulsant properties — it reduces neuronal excitability through CB1 receptor activation. At high doses, THC can be proconvulsant in some patients. This is why low-THC, high-CBD ratios are recommended for epilepsy. A small amount of THC (2–5% of the total cannabinoid content) may actually enhance CBD's anticonvulsant effects. Many Florida patients with epilepsy find that a 20:1 or 10:1 CBD:THC product works better than pure CBD, potentially because THC helps CBD cross the blood-brain barrier more effectively and activates complementary anticonvulsant pathways. However, epilepsy patients should avoid high-THC products and should never significantly increase their THC dose without physician guidance. Dr. Stratt works closely with patients' neurologists to ensure cannabis therapy is safely integrated with existing anticonvulsant regimens.

Cannabis for Different Epilepsy Types

Not all epilepsy is the same, and response to CBD varies by seizure type. Dravet syndrome: the strongest evidence — CBD reduces convulsive seizures by 39–50% in RCTs. High-dose CBD (5–10 mg/kg twice daily) is typically needed. Lennox-Gastaut syndrome: strong evidence — CBD reduces drop seizures by 42% in RCTs. Response may take 4–8 weeks to fully manifest. Focal epilepsy: moderate evidence from open-label trials. CBD may reduce seizure frequency by 30–50%, with some patients achieving seizure freedom. Temporal lobe epilepsy: the most common adult epilepsy — anecdotal evidence is strong, but RCT data is limited. Many Florida patients report significant improvement. Absence seizures: limited data. Some patients report benefit, but absence seizures are a different mechanism than convulsive seizures, and evidence is insufficient to make strong recommendations. Status epilepticus: emergency rescue use of CBD is not established. Conventional emergency treatments (benzodiazepines) remain the standard of care. CBD should be viewed as a preventive maintenance therapy, not an acute rescue medication.

Getting Certified for Epilepsy in Florida

Epilepsy is explicitly listed as a qualifying condition under Florida Statute 381.986. Bring your seizure diary, neurologist records, EEG reports, and a list of anticonvulsant medications you've tried. If your seizures are not fully controlled by current medications (which is the case for roughly 30% of epilepsy patients), you're a strong candidate for medical cannabis certification. Dr. Stratt coordinates with your neurologist to ensure cannabis therapy is safely integrated with your existing treatment plan — including monitoring for drug interactions with anticonvulsants. For pediatric epilepsy patients (under 18), additional requirements apply including a second physician concurrence, but the process is well-established in Florida given the strong evidence for CBD in pediatric epilepsy syndromes.